The Patent Finder

Intrexon Corporation

18 patents currently held · Updated Nov 15, 2026
31 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 6 name spellings.

Recorded as renamed to Precigen, Inc. (2020)

9
Ending by 2030
May 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 11, 2027
    The maintenance fee for Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex (US 9,102,648) comes due Feb 11, 2027. Unpaid by Aug 11, 2027, it lapses early.
  • 1 fee due Apr 20, 2027
    The maintenance fee for Mutant Receptors and Their Use in a Nuclear Receptor-Based Inducible Gene Expression System (US 9,163,256) comes due Apr 20, 2027. Unpaid by Oct 20, 2027, it lapses early.
  • 2 fees due Jun 10, 2027
  • 1 fee due Sep 10, 2027
    The maintenance fee for Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof (US 10,584,351) comes due Sep 10, 2027. Unpaid by Mar 10, 2028, it lapses early.
  • 1 fee due Oct 28, 2027
    The maintenance fee for Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex (US 10,633,361) comes due Oct 28, 2027. Unpaid by Apr 28, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 17, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 9,034,650Site-specific serine recombinases and methods of their use
In force
 · High confidence
In forceHigh confidence
US 7,705,122Mtor Ligands and Polynucleotides Encoding Mtor Ligands
In force
 · High confidence
In forceHigh confidence
US 8,884,060Process of Preparing Chiral Diacylhydrazine Ligands
In force
 · Medium confidence
In forceMedium confidence
US 9,675,642Engineered Dendritic Cells and Uses for the Treatment of Cancer
In force
 · Medium confidence
In forceMedium confidence
US 9,163,256Mutant Receptors and Their Use in a Nuclear Receptor-Based Inducible Gene Expression System
In force
 · Medium confidence
In forceMedium confidence
US 10,633,361Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex
In force
 · Medium confidence
In forceMedium confidence
US D742,785Container
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,114,024Seal for a rotating shaft
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,102,648Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex
In force
 · Medium confidence
In forceMedium confidence
US 10,584,351Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof
In force
 · Medium confidence
In forceMedium confidence
10 of 18 patents shown.
Pro members see all 18.
Pro members: see all 18 patents
Also on record, not counted in the 18: 31 patents in force now held by others · 88 lapsed for an unpaid fee · 48 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 7 abandoned · 46 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited